TY  - CHAP
M1  - Book, Section
TI  - Atopic Dermatitis
A1  - Law, Rebecca M.
A1  - Kwa, Po Gin
A2  - DiPiro, Joseph T.
A2  - Talbert, Robert L.
A2  - Yee, Gary C.
A2  - Matzke, Gary R.
A2  - Wells, Barbara G.
A2  - Posey, L. Michael
PY  - 2017
T2  - Pharmacotherapy: A Pathophysiologic Approach, 10e
AB  - Content  UpdateMay  16,  2017Dupilumab  (Dupixent®)  Approved  for  Moderate  to  Severe  Atopic  Dermatitis:  Dupilumab  is  a  monoclonal  antibody  that  binds  to  the  interleukin-4  (IL-4)  receptor  alpha  subunit  (IL-4rα),  inhibiting  the  inflammatory  response  involved  in  development  of  atopic  dermatitis  (AD).  It  is  approved  for  treatment  of  adults  with  moderate-to-severe  AD  whose  disease  is  not  adequately  controlled  with  topical  prescription  therapies  or  when  those  therapies  are  not  advisable.  Three  phase  3  clinical  trials  demonstrated  improved  AD  symptoms  when  compared  to  placebo;  no  comparative  trials  with  other  systemic  therapies  have  been  conducted.  Side  effects  are  generally  mild  and  include  injection  site  reactions,  conjunctivitis,  blepharitis,  oral  herpes,  keratitis,  eye  pruritus,  and  dry  eye.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/16
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1145203809
ER  -